

AssayMax™ Human Serum Amyloid A ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

Assay Summary

Step 1. Add 50 μl of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μ l of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 15 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key



Consult instructions for use.

Assay Template

12								
11								
10								
6								
80								
7								
9								
4								
æ								
2								
1								
	Ą	В	0	Q	E	F	9	I

AssayMax™ Human Serum Amyloid A (SAA) ELISA Kit

Catalog No. EA8001-7

Sample insert for reference use only
Positive Control Included

Introduction

Human serum amyloid A (SAA) is a major apolipoprotein of high-density lipoprotein in plasma and a sensitive marker of acute inflammation. It is not only synthesized by the liver and adipose tissue but also produced extrahepatically by many cancers (1). SAA is a 12.5-kDa protein containing 122 amino acids with polymorphic forms (2-3). Four SAA genes have been identified and three encode functional proteins in humans. In response to inflammatory stimuli, acute-phase SAA1 and SAA2 are secreted and increased. SAA3 is a pseudogene that does not express protein. SAA4 is expressed constitutively in the liver (4). SAA is associated with obesity, amyloidosis, type 2 diabetes, atherosclerosis, metabolic syndrome, rheumatoid arthritis, and renal and lung cancers (5-9).

Principle of the Assay

The AssayMax™ Human Serum Amyloid A ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of SAA in human plasma, serum, and cell culture samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures total human SAA in approximately 4 hours. A polyclonal antibody specific for human SAA has been pre-coated onto a 96-well microplate with removable strips. SAA in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human SAA, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- This product is for Research Use Only and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate) as instructed, prior to running the assay.

- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial, the biotinylated antibody vial, and the standard diluent vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human Serum Amyloid A Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human SAA.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human Serum Amyloid A Standard: Human SAA in a buffered protein base, calibrated against WHO 1st International Standard (14 μg, lyophilized).
- Biotinylated Human Serum Amyloid A Antibody (50x): A 50-fold concentrated biotinylated polyclonal antibody against human SAA (120 μl).
- MIX Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Standard Diluent (1x): A buffered protein base with stabilizer (2 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 μl).
- Chromogen Substrate (1x): A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- Stop Solution (1x): A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).
- Positive Control: 1 vial, lyophilized. See insert CEA80011.

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store Standard, SP Conjugate, and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Standard Diluent (1x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.

Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

- Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. An 8-fold sample dilution is suggested into MIX Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- **Serum:** Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. An 8-fold sample dilution is suggested into MIX Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Cell Culture Supernatant: Centrifuge cell culture media at 1500 rpm for 10 minutes at 4°C to remove debris and collect supernatant. Samples can be stored at -80°C. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	(for reference only; please follow the	inser	t for specific dilution suggested)
	100x		10000x
A)	4 μl sample: 396 μl buffer (100x) = 100-fold dilution	A) B)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution
	Assuming the needed volume is less than or equal to 400 μ l.		Assuming the needed volume is less than or equal to 400 μ l.
	1000x		100000x
A)	4 μl sample : 396 μl buffer (100x)	A)	4 μl sample : 396 μl buffer (100x)
B)	24 μl of A : 216 μl buffer (10x)	B)	4 μl of A : 396 μl buffer (100x)
	= 1000-fold dilution	C)	24 μl of B : 216 μl buffer (10x) = 100000-fold dilution
	Assuming the needed volume is less than or equal to 240 μl.		Assuming the needed volume is less than or equal to 240 μl.

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- MIX Diluent Concentrate (10x): Dilute the MIX Diluent Concentrate 10fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved. Store for up to 30 days at 2-8°C.
- Human Serum Amyloid A Standard: Reconstitute the Human Serum Amyloid A Standard (14 μg, 13.44 mIU) with 0.7 ml of Standard Diluent to generate a 20 μg/ml (19.2 mIU/ml) standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. From the standard stock solution (20 μg/ml), dilute 10-fold with MIX Diluent to produce a 2 μg/ml standard working solution. Prepare duplicate or triplicate standard points by serially diluting the standard working solution (2 μg/ml) 2-fold with equal volume of MIX Diluent to produce 1, 0.5, 0.25, 0.125, 0.063, and 0.031 μg/ml solutions. MIX Diluent serves as the zero standard (0 μg/ml). Aliquot remaining stock solution to limit repeated freeze-thaw cycles. This solution should be stored at -20°C and used within 30 days.

Standard	Dilution	[SAA]	[SAA]

Point		(μg/ml)	(mIU/ml)
P1	1 part Standard + 9 parts MIX Diluent	2.0	1.92
P2	1 part P1 + 1 part MIX Diluent	1.0	0.96
Р3	1 part P2 + 1 part MIX Diluent	0.5	0.48
P4	1 part P3 + 1 part MIX Diluent	0.25	0.24
P5	1 part P4 + 1 part MIX Diluent	0.125	0.12
P6	1 part P5 + 1 part MIX Diluent	0.063	0.06
P7	1 part P6 + 1 part MIX Diluent	0.031	0.03
P8	MIX Diluent	0.0	0.0

- Biotinylated Human Serum Amyloid A Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with MIX Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 100-fold with MIX Diluent to produce a 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them
 immediately to the foil pouch with desiccants inside. Reseal the pouch
 securely to minimize exposure to water vapor and store in a vacuum
 desiccator.
- Add 50 µl of Human Serum Amyloid A Standard or sample to each well.
 Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If washing manually, wash five times with 200 µl of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer, wash six times with 300 µl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.

- Add 50 µl of Biotinylated Human Serum Amyloid A Antibody to each well.
 Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate for 15 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections.
 Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data

The typical data is provided for reference only. Individual laboratory
means may vary from the values listed. Variations between laboratories
may be caused by technique differences.


Standard Point	μg/ml	OD	Average OD
P1	2.0	2.041	2.019

		1.997	
P2	1.0	1.392	1.374
r Z	1.0	1.356	1.574
P3	0.5	0.827	0.813
ro	0.5	0.799	0.813
P4	0.25	0.487	0.476
Г4	0.23	0.465	0.470
P5	0.125	0.289	0.283
ro	0.123	0.277	0.283
P6	0.063	0.193	0.189
FU	0.003	0.185	0.169
P7	0.031	0.158	0.155
Γ/	0.031	0.152	0.133
P8	0.0	0.102	0.101
FΟ	0.0	0.100	0.101
Sample: Poo	oled Normal	0.566	0.500
Sodium Citrat	e Plasma (8x)	0.554	0.560


Standard Curve

• The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Human SAA Standard Curve



Human SAA Standard Curve



Reference Value

Normal human SAA plasma levels are less than 5 μg/ml.

Performance Characteristics

- Kit standard has been calibrated against WHO International Standard.
- This assay recognizes both natural and recombinant human SAA.
- The minimum detectable dose of human SAA as calculated by 2SD from the mean of a zero standard was established to be 21 ng/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

	Intra-Assay Precision			Inter	-Assay Prec	ision
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	5.5%	6.3%	6.1%	9.3%	10.2%	9.8%
Average CV (%)	6.0%				9.8%	

Spiking Recovery

 Recovery was determined by spiking two plasma samples with different SAA concentrations.

Sample	Unspiked Sample (µg/ml)	Spiking Value (µg/ml)	Expected	Observed	Recovery (%)
	1 0.55	0.15	0.70	0.80	114%
1		0.30	0.85	0.89	105%
		1.00	1.55	1.49	96%
		0.15	1.35	1.40	104%
2	2 1.20	0.30	1.50	1.45	97%
		2.16	98%		
Average Recovery (%)					102%

Linearity

Plasma and serum samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)				
Sample Dilution	Plasma	Serum		
4x	91%	92%		
8x	101%	98%		
16x	109%	109%		

Cross-Reactivity

Species	Cross-Reactivity (%)
Canine	<20%
Bovine	None
Monkey	None
Mouse	None
Rat	<10%
Swine	<20%
Rabbit	None

• 10% FBS in culture media will not affect the assay.

Note

The conversion of IU to mg is 1 International Unit (1 IU) = 1.04 mg.

Troubleshooting

Issue	Causes	Course of Action
	Use of improper	Check the expiration date listed before use.
	components	 Do not interchange components from different lots.
		Check that the correct wash buffer is being used.
		 Check that all wells are empty after aspiration.
	Improper wash step	 Check that the microplate washer is dispensing properly.
		 If washing by pipette, check for proper pipetting
_		technique.
Low Precision	Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.
J.e	Inconsistent volumes	 Pipette properly in a controlled and careful manner.
_ ₹	loaded into wells	 Check pipette calibration.
و ا		Check pipette for proper performance.
	Insufficient mixing of	 Thoroughly agitate the lyophilized components after
	reagent dilutions	reconstitution.
		Thoroughly mix dilutions.
	las anno andre on a lord	Check the microplate pouch for proper sealing.
	Improperly sealed	Check that the microplate pouch has no punctures.
	microplate	Check that three desiccants are inside the microplate pouch prior to scaling.
	Microplate was left	pouch prior to sealing. • Each step of the procedure should be performed
<u>_</u>	unattended between	uninterrupted.
l iii	steps	uninterrupteu.
Unexpectedly Low or High Signal Intensity	Omission of step	Consult the provided procedure for complete list of steps.
gh	Steps performed in	Consult the provided procedure for the correct order.
王	incorrect order	· ·
ço	Insufficient amount of	Check pipette calibration.
y ×	reagents added to	 Check pipette for proper performance.
ly Low o	wells	
를 들	Wash step was skipped	Consult the provided procedure for all wash steps.
Ę	Improper wash buffer	 Check that the correct wash buffer is being used.
) e	Improper reagent	Consult reagent preparation section for the correct
X	preparation	dilutions of all reagents.
ן בַּ	Insufficient or prolonged incubation	 Consult the provided procedure for correct incubation time.
_	prolonged incubation periods	ume.
	perious	Sandwich ELISA: If samples generate OD values higher
		than the highest standard point (P1), dilute samples
臣		further and repeat the assay.
Š	Non-optimal sample	Competitive ELISA: If samples generate OD values lower
ב	dilution	than the highest standard point (P1), dilute samples
5		further and repeat the assay.
ar		 User should determine the optimal dilution factor for
pu		samples.
Sta	Contamination of	A new tip must be used for each addition of different
=	reagents	samples or reagents during the assay procedure.
Deficient Standard Curve Fit	Contents of wells	Verify that the sealing film is firmly in place before placing
j≟	evaporate	the assay in the incubator or at room temperature.
De	Impropor pipotti	Pipette properly in a controlled and careful manner. Check pipette calibration.
	Improper pipetting	Check pipette calibration. Check pipette for proper performance.
		 Check pipette for proper performance.

	Insufficient mixing of reagent dilutions	 Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.
--	--	--

References

- (1) Malle E et al. (2009) Cell Mol Life Sci. 66(1):9-26.
- (2) Kluve-Beckerm B et al. (1986) Biochem Genet. 24(11-12):795-803.
- (3) Sipe JD et al. (1985) Biochemistry. 24(12):2931-2936.
- (4) Watson G et al. (1992) Scand J Immunol. 36(5):703-712.
- (5) Yang RZ et al. (2006) PLoS Med. 3(6):e287.
- (6) Malle E et al. (2009) Cell Mol Life Sci. 66:9-26.
- (7) Uhlar CM, Whitehead AS. (1999) Eur J Biochem. 265:501-523.
- (8) Wood SL et al. (2010) Br J Cancer. 103(1):101-111.
- (9) Howard BA et al. (2003) Proteomics. 3(9):1720-1724.

Version 3.5-7